Welcome to our dedicated page for CAMP4 Therapeutics Corporation news (Ticker: CAMP), a resource for investors and traders seeking the latest updates and insights on CAMP4 Therapeutics Corporation stock.
CalAmp Corp. (Nasdaq: CAMP) is a pioneering leader in the Internet of Things (IoT) revolution, offering a rich portfolio of intelligent communication devices, a robust cloud platform, and bespoke software applications. The company specializes in helping customers optimize their operations by collecting, monitoring, and efficiently reporting critical data and intelligence from high-value remote assets.
With over five million devices connected to its IoT cloud, CalAmp serves a diverse range of markets including transportation, oil and gas, and public safety. The company’s technology enables organizations to make actionable decisions based on mission-critical data. Its Telematics Systems segment provides Mobile Resource Management (MRM) products and applications, while the Software & Subscription Services segment delivers cloud-based application enablement and telematics service platforms.
Recent achievements highlight CalAmp's commitment to innovation and financial stability. In its latest financial quarter, the company generated a positive cash flow from operations amounting to $7.1 million and achieved a robust Adjusted EBITDA of $5.9 million. New product releases such as Vision 2.0 and ELD solutions have been key drivers of growth. Furthermore, CalAmp recently secured a $45 million term loan to support its transformative business strategies.
CalAmp's strategic initiatives include a focus on enhancing operational efficiencies and capturing new market opportunities, despite facing revenue headwinds in specific segments like TSP. The company continues to work closely with its partners to navigate competitive pressures and align inventory levels with market demand.
Looking forward, CalAmp aims to return to profitable growth by leveraging its strong product portfolio, including over 10 million active edge devices and more than 275 approved or pending patents. The company’s significant investment in R&D ensures that it remains at the forefront of telematics innovation, providing dependable solutions that improve efficiency, safety, and compliance for both commercial and government organizations worldwide.
For more information, please visit www.calamp.com.
CAMP4 Therapeutics (Nasdaq: CAMP), a clinical-stage biotech company specializing in regRNA-targeting antisense oligonucleotide (ASO) therapies, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's President & CEO, Josh Mandel-Brehm, will deliver a corporate update presentation on Wednesday, January 15, 2025, at 3:45 p.m. PST in San Francisco, California.
The presentation will be available through a live webcast on CAMP4's investor relations website. Interested parties can access the webcast at www.investors.camp4tx.com, and a replay will remain available on the company's website for 30 days after the conference.
CAMP4 Therapeutics provided corporate updates and key objectives for 2025, highlighting significant progress in their clinical programs. The company completed its IPO, raising gross proceeds of $82.1 million. Their lead program, CMP-CPS-001 for urea cycle disorders (UCDs), demonstrated favorable safety results in the Single Ascending Dose (SAD) portion of Phase 1 study, with all treatment emergent adverse events being mild or moderate.
The company has completed dosing in the first two Multiple Ascending Dose (MAD) cohorts and initiated Cohort 3. The FDA granted both Rare Pediatric Disease Designation and Orphan Drug Designation to CMP-CPS-001. CAMP4 also entered a strategic research collaboration with BioMarin and was added to the Russell 2000® Index. Key upcoming milestones include MAD safety and biomarker data expected in 2H 2025, and the initiation of a new discovery program targeting GBA1 regRNA for Parkinson's disease treatment.
CAMP4 Therapeutics has appointed John Maraganore, Ph.D., and Rachel Meyers, Ph.D., as strategic advisors. Both bring extensive experience in RNA-based medicines to the company.
Dr. Maraganore, former CEO of Alnylam, led the development and commercialization of the first four RNAi therapeutics. He also has a background in oncology, cardiovascular, inflammatory, and metabolic diseases from his time at Millennium Pharmaceuticals.
Dr. Meyers, with over two decades in life sciences, was Senior VP of Research at Alnylam and is currently on several scientific advisory boards. She has significant expertise in developing RNA-based therapies and has held leadership roles in various biotech firms.
CEO Josh Mandel-Brehm expressed excitement about leveraging their expertise to advance CAMP4's RNA Actuating platform, aiming to upregulate gene expression to treat genetic diseases. Both advisors see potential for CAMP4 to impact a broad range of diseases through innovative RNA medicines.
CAMP4 Therapeutics (Nasdaq: CAMP), a clinical-stage biotechnology company, announced its participation in the Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace Hotel, NYC, from December 3-5, 2024. CAMP4's management will present on December 5, 2024, from 1:00-1:25 PM ET.
The presentation will be available via a live webcast on the company's investor relations website. For meeting requests or more details, contact your institutional representative or email the company.
CAMP4 Therapeutics reported Q3 2024 financial results and corporate updates. The company completed an IPO raising $82.1M in gross proceeds. Key highlights include completing the Single Ascending Dose portion of Phase 1 study for CMP-CPS-001, with safety data expected in Q1 2025, and entering a strategic collaboration with BioMarin valued at over $370M. The company reported a net loss of $13.5M for Q3 2024, with R&D expenses at $9.7M and G&A expenses at $3.8M. Cash position was $2.5M at quarter-end, strengthened by the IPO proceeds.
CAMP4 Therapeutics (Nasdaq: CAMP), a clinical-stage biotechnology company, has announced the pricing of its initial public offering (IPO). The company is offering 6,820,000 shares of common stock at $11.00 per share, aiming to raise approximately $75.0 million in gross proceeds. Trading of CAMP4's common stock on the Nasdaq Global Market is expected to begin on October 11, 2024, under the ticker symbol 'CAMP'.
The offering is set to close on October 15, 2024, subject to customary conditions. CAMP4 has also granted the underwriters a 30-day option to purchase up to an additional 1,023,000 shares at the IPO price. J.P. Morgan, Leerink Partners, Piper Sandler, and William Blair are acting as joint book-running managers for the offering.
CalAmp (Nasdaq: CAMP) has announced a Restructuring Support Agreement (RSA) with Lynrock Lake Master Fund LP, its principal secured lender, to significantly reduce debt and take the company private. Lynrock will exchange approximately $229 million of Convertible Senior Secured Notes into equity interests, becoming the principal equity owner. Despite the Chapter 11 filing, operations will continue without disruption. This move aims to enhance financial flexibility, allowing CalAmp to invest in innovation and support evolving customer needs. The restructuring plan is expected to navigate swiftly with court approval, reinforcing CalAmp's financial health and operational capabilities.
CalAmp has launched Dispatch Monitor, a new application that integrates with their K-12 suite of solutions, aimed at improving school bus fleet management. The application provides real-time route coverage visibility, enhances driver efficiency, and prioritizes student safety. Dispatch Monitor offers tools to streamline operations and optimize transportation experiences for both students and administrators.